BioSpace News Archive

Quote from Andrew Winner, Product Manager, Lonza Bioscience: “The short viability window of fresh Leukopaks means researchers are at the mercy of donor and shipping schedules – and any logistical delays can wreak havoc on project costs and the quality of research results

Data presented have been submitted to U.S. and EU regulatory agencies and represent an important step towards addressing the high unmet need in this patient population

Senseonics Holdings, Inc. announced the closing on January 26, 2021, of its previously announced public underwritten offering of 59,740,259 shares of common stock of the Company, including the exercise in full by the underwriter of its option to purchase an additional 7,792,207 shares of common stock which closed yesterday, at a public offering price of $1.925 per share.

Several leading international lung cancer researchers at a press today presented compelling new data revealing that factors of race, gender, sexual orientation and income continue to be significant barriers to those living with lung cance

Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock, at a public offering price of $15.00 per share, before underwriting discounts and commissions.

Novotech Health Holdings, the largest biotech specialist contract research organization in Asia, announced the appointment of Andy Liu as Head of China.

Repositive has announced today that IDMO will be joining its global network of CRO partners.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced its support and presentation in the Melanoma Research Foundation’s “Ask the Expert” webinar series throughout the month of January.

A team of scientists at Gladstone Institutes and UC San Francisco (UCSF) is launching the Gladstone-UCSF Center for Neurovascular Brain Immunology to study neurological diseases in a unique way that could lead to the development of novel treatments.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) , a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced its intention to offer its American Depositary Shares (“ADSs”) in an underwritten public offering